JFrog Ltd. Ordinary Shares vs Sana Biotechnology Inc — how do they compare? JFrog Ltd. Ordinary Shares trades at $97.61 (market cap $12.10B), while Sana Biotechnology Inc trades at $2.76 (market cap $812.76M). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 14.9× Sana Biotechnology Inc's market cap, and JFrog Ltd. Ordinary Shares is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 0 Days and Sana Biotechnology Inc for 23 Days on average.
| FROG | SANA | |
|---|---|---|
Market Cap | $12.10B | $812.76M |
Volume | 773,694 | 4,314,200 |
Sector | Technology | Health |
52-Week High | $104.03 | $5.92 |
52-Week Low | $34.75 | $2.68 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.29B | $726.01M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →